News

News selection

In the following you will find news from Polypharma Technologies & Sciences GmbH and the pharmaceutical industry.

Diclofenac diethylamine 1% gel

Polypharma has completed the preparation of a technical dossier for a gel based on 1% diethylamine diclofenac. Diclofenac diethylamine has an analgesic, anti-inflammatory and refreshing effect. It can be used to treat sports injuries, sunburn and arthritis.

read more

Calcipotriol ointment developed

With this ointment Polypharma is also expanding its portfolio of dermatology products. A product extremely effective for the external treatment of psoriasis. This D3 derivative disrupts the growth and proliferation of keratinocytes and improves the disturbed cell separation.

read more

High concentration drugs now injectable

The researchers designed a system that made it possible to inject highly concentrated drug formulations subcutaneously while reducing the required injection force, which exceeded what is possible with manual subcutaneous injection using a conventional syringe.

read more

The impact of indoor air humidity content on Covid-19

Humidity levels of at least 40% in public buildings and public transport would not only reduce the impact of COVID-19, but also that of other viral diseases such as seasonal influenza. Authorities should incorporate the humidity factor into future guidelines for interiors.

read more

Formulations that enhance bioavailability

It is useful to combine in vitro testing and in silico modelling to predict and understand the in vivo performance of formulations that improve bioavailability, resulting in a successful in vivo test for belinostat. The key factor for in vivo performance was determined to be dissolution in the stomach prior to transit in the proximal small intestine, as evidenced by in vitro data and in silico predictions.

read more

Water Activity determination

Water activity (Aw) is a measure of the activity of free or unbound water that is available to participate in undesirable chemical, physical and biological reactions. Measurement of water activity at multiple time points during the product life cycle will be related to changes in critical quality attributes such as degradation of the active ingredient, changes in the rate of dissolution or disintegration and changes in physical properties such as hardness or friability. Controlling water...

read more

Bempedoic acid inhibit cholesterol biosynthesis

Bempedoic acid is a new class of nonstatin LDL-lowering therapy that has been approved for the European market since April 2020. Bempedoic acid can be used as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease requiring additional lowering of LDL-C.

read more

Fusidic acid and betamethasone creme developed

Polypharma has developed a cream containing the active ingredients fusidic acid and betamethasone. While fusidic acid is known to help with bacterial infections of the skin, betamethasone helps with skin diseases such as psoriasis, neurodermatitis and hives. It is well known that in patients with neurodermatitis, bacteria often occur on the skin, causing inflammation and worsening the course of the disease. In addition to neurodermatitis, this dual-therapy helps to reduce the bacteria and thus...

read more

Novel Analytical Techniques to Accelerate Biopharmaceutical Development

Rapid and adaptable evaluation of monoclonal antibody therapeutics using the Fc receptor panel test based on Octet System before selection of the final molecule. The Octet system optimises itself for each new mAb, optimising the buffer and background conditions, thus minimising any non-specific interactions that might occur. Once this is done, it is necessary to optimise the association and dissociation times of the receptors with that antibody. Accuracy and optimisation are the points...

read more

Polypharma
Technologies & Sciences GmbH

Grosse Reichenstrasse 27
20457 Hamburg
Germany
+49 (0)40 37 480 3-0
info[at]polypharma.de